{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-7541", "postId": 7541, "name": "Rezolute, Inc.", "description": "If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (\u201cRezolute\u201d or the \u201cCompany\u201d) (NASDAQ: RZLT). STOCK DROP: Rezolute, Inc. shares tumbled sharply on December 11, 2025, as investors reacted to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism. The study failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant versus placebo. During intraday trading, RZLT collapsed from levels near its prior day close of around $10.94 to an intraday low near $0.90, representing an approximate 85\u201390% drop as markets opened and halted trading under Nasdaq\u2019s volatility controls.", "identifier": "RZLT", "legal": { "court": "", "jurisdiction": "" }, "classPeriod": { "start": "", "end": "" }, "leadPlaintiffDeadline": "", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/rezolute-inc/", "canonicalUrl": "https://faruqilaw.com/case/rezolute-inc/", "datePublished": "2025-12-11T18:37:36+00:00", "dateModified": "2025-12-11T18:37:36+00:00", "associatedOrganization": { "@id": "case-7541-org" }, "legalService": { "@id": "case-7541-legalservice" }, "hasPart": [ { "@id": "case-7541-faq" }, { "@id": "case-7541-press-list" } ], "legalRepresentation": [ { "@id": "case-7541-attorney-516" }, { "@id": "case-7541-attorney-506" } ] }, { "@type": "Organization", "@id": "case-7541-org", "name": "Rezolute, Inc.", "identifier": "RZLT", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg" }, { "@type": "LegalService", "@id": "case-7541-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-7541-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-7541-legalservice" } }, { "@type": "Person", "@id": "case-7541-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-7541-legalservice" } } ] }

Rezolute, Inc.

Rezolute, Inc.

Join Action

If you are a Rezolute investor who suffered a loss and would like to learn more, you can provide your information below

If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT).

STOCK DROP: Rezolute, Inc. shares tumbled sharply on December 11, 2025, as investors reacted to disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, its lead drug candidate for treating congenital hyperinsulinism. The study failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant versus placebo.

During intraday trading, RZLT collapsed from levels near its prior day close of around $10.94 to an intraday low near $0.90, representing an approximate 85–90% drop as markets opened and halted trading under Nasdaq’s volatility controls.

Join Action
Rezolute, Inc.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
New York
685 Third Avenue 26th Floor New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771